Related references
Note: Only part of the references are listed.Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis
Nicolas A. Nunez et al.
JOURNAL OF AFFECTIVE DISORDERS (2022)
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2022)
Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials
Siyuan Yang et al.
PSYCHIATRIC QUARTERLY (2022)
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment
Jason Ng et al.
PSYCHOPHARMACOLOGY (2021)
Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression
Filippo Cantu et al.
JOURNAL OF AFFECTIVE DISORDERS (2021)
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre et al.
AMERICAN JOURNAL OF PSYCHIATRY (2021)
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
Enrico Capuzzi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review
Jolien K. E. Veraart et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)
Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Giovanni Martinotti et al.
BRAIN SCIENCES (2021)
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies
Ibrahim Turkoz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2021)
The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
Maryia Zhdanava et al.
JOURNAL OF CLINICAL PSYCHIATRY (2021)
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
Rachel Ochs-Ross et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)
Rapid effects of S-ketamine on the morphology of hippocampal astrocytes and BDNF serum levels in a sex-dependent manner
Maryam Ardalan et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Cheolmin Shin et al.
PSYCHIATRY INVESTIGATION (2020)
Pharmacological Treatments for Patients with Treatment-Resistant Depression
Valerie L. Ruberto et al.
PHARMACEUTICALS (2020)
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
Ewa Wajs et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Mohammed S. Salahudeen et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2020)
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Esketamine for treatment resistant depression
Jennifer Swainson et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Maggie Fedgchin et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2019)
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Sanne Y. Smith-Apeldoorn et al.
BMC PSYCHIATRY (2019)
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2018)
Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism
Lily R. Aleksandrova et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2017)
Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression
Bradley Gaynes
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Yong-Ku Kim et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
Carlos A. Zarate et al.
BIOLOGICAL PSYCHIATRY (2012)
Chronic ketamine use increases serum levels of brain-derived neurotrophic factor
Valerio Ricci et al.
PSYCHOPHARMACOLOGY (2011)
Rapid Resolution of Suicidal Ideation After a Single Infusion of an N-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Nancy DiazGranados et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Carlos A. Zarate et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Moderate and severe depression gradations for the Montgomery-Asberg Depression Rating Scale
MJ Müller et al.
JOURNAL OF AFFECTIVE DISORDERS (2000)